| [1] |
Li HX, Guan XY, Zhang SM, et al. Study on the relationship of taxol-resistance of ovarian carcinoma with the amplification of 2p 22 on chromosome and the expression of hmsh2 gene[J]. Zhong Liu Fang Zhi Yan Jiu, 2006, 33(8): 565-7. [李红霞, 关兴元, 张 素梅, 等. 染色体2p22的过度扩增及hmsh2基因的高表达与卵 巢癌紫杉醇耐药相关性的研究[J]. 肿瘤防治研究, 2006, 33(8): 56 5-7.]
|
| [2] |
Wang AX, Li J, Li H. Study on RNA interference silencing hMSH2 induces the reversal chemo-resistance of ovarian carcinoma cell line OC3/TAX300[J]. Zhonghua Fu Chan Ke Za Zhi, 2014, 49(3): 21 3-7. [王爱新, 李健, 李红霞. 沉默hMSH2基因表达对紫杉醇 耐药的卵巢上皮性癌OC3/TAX300细胞耐药性的影响[J]. 中华 妇产科杂志, 2014, 49(3): 213-7.]
|
| [3] |
Zhang W. Clinical application of in vitro drug sensitivity assay for tumor using ATP-TCA[J]. Ai Zheng Jin Zhan, 2005, 3(5): 427-35. [张伟. 生物荧光肿瘤体外药敏检测技术的临床应用及其探讨 [J] 癌症进展, 2005, 3(5): 427-35.]
|
| [4] |
Zhao D, Zhang W, Li XG, et al. Predicting clinical chemosensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes[J]. Zhonghua Fu Chan Ke Za Zhi, 2011, 46(3): 193-8. [赵丹, 张伟, 李晓光, 等. 三磷酸腺苷- 肿瘤体外药敏试验联合耐药基因检测预测原发性卵巢癌的化 疗敏感性[J]. 中华妇产科杂志, 2011, 46(3): 193-8.]
|
| [5] |
Chang QY, Wu LY, Li XG, et al. Cost-effectiveness of adenosine triphosphate-tumor chemosensitivity assay in advanced epithelial ovarian cancer chemotherapy[J]. Ai Zheng Jin Zhan, 2011, 9(2): 19 1-5,216. [常青云, 吴令英, 李晓光, 等. 三磷酸腺苷-肿瘤体外 药敏检测在晚期卵巢上皮癌化疗中的成本－效果评价[J]. 癌症 进展, 2011, 9(2): 191-5,216. ]
|
| [6] |
Neubauer H, Stefanova M, Solomayer E, et al. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer[J]. Anticancer Res, 2008, 28(2A): 949-55.
|
| [7] |
Marcelis CL, van der Putten HW, Tops C, et al. Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation?[J]. Fam Cancer, 2001, 1(2): 107-9.
|
| [8] |
Gu GL, Zhu XQ, Wei XM, et al. Epithelial-mesenchymal transition in colorectal cancer tissue of patients with Lynch syndrome[J]. World J Gastroenterol, 2014, 20(1): 250-7.
|
| [9] |
Masuda K, Banno K, Hirasawa A, et al. Relationship of lower uterine segment cancer with Lynch syndrome: a novel case with an hMLH1 germline mutation[J]. Oncol Rep, 2012, 28(5): 15 37-43.
|
| [10] |
Yasin SL, Rainbow AJ. A combination of MSH2 DNA mismatch repair deficiency and expression of the SV40 large T antigen results in cisplatin resistance of mouse embryonic fibroblasts[J]. Int J Oncol, 2011, 39(3): 719-26.
|
| [11] |
Materna V, Surowiak P, Markwitz E, et al. Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients[J]. Oncol Rep, 2007, 17(3): 50 5-16.
|
| [12] |
Vageli DP, Zaravinos A, Daniil Z, et al. hMSH2 and hMLH1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma: correlation with patient survival and response to adjuvant chemotherapy treatment[J]. Int J Biol Markers, 2013, 27(4): e400-4.
|
| [13] |
Li SN, Li L, Wang CZ. Expressions of hMSH2 and MGMT proteins in endometrial caicinoma[J]. Dalian Yi Ke Da Xue Xue Bao, 2011, 33(5): 430-3. [李斯宁, 李玲, 王长智. hMSH2、 MGMT在子宫内膜癌中的表达及其病理意义[J]. 大连医科大 学学报, 2011, 33(5): 430-3.]
|
| [14] |
Nadin SB, Vargas-Roig LM, Drago G, et al. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy[J]. Cancer Lett, 2006, 239(1): 84 -97.
|
| [15] |
Steffensen KD, Smoter M, Waldstrøm M, et al. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression[J]. Int J Oncol, 2014, 44(5): 1736-44.
|
| [16] |
Li QQ, Lee RX, Liang H, et al. β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK[J]. Int J Oncol, 20 13, 43(3): 721-8.
|
| [17] |
Mohammed MZ, Vyjayanti VN, Laughton CA, et al. Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines[J]. Br J Cancer, 2011, 104(4): 653-63.
|
| [18] |
Syrios J, Banerjee S, Kaye SB. Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets-where are we now?[J]. Anticancer Res, 2014, 34 (5): 2069-77.
|
下载:
